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ABSTRACT 
Objectives: To compare the frequency of PPM with self-expandable valves (SEV) to 
balloon-expandable valves (BEV). 
Background: Prosthesis-patient mismatch (PPM) has been associated with increased 
mortality after transcatheter aortic valve replacement. Data on the frequency of PPM as a 
function of supra-annular or intra-annular position of transcatheter heart valves is 
insufficient. 
Methods: A total of 757 patients treated with SEV (CoreValve, Evolut R) and BEV 
(SAPIEN THV/XT/3) were enrolled in the present analysis between August 2007 and 
June 2017. PPM was classified based on discharge prosthetic effective orifice area 
indexed to BSA as severe (<0.65 cm2/m2) or moderate (0.65 to 0.85 cm2/m2) in the general 
population, and as severe (<0.60 cm2/m2) or moderate (0.60 to 0.90 cm2/m2) in the obese 
population (BMI ≥ 30 kg/m2). 
Results: Propensity score matching resulted in 224 matched pairs. At discharge, SEV 
were associated with a lower incidence of PPM compared with BEV (PPM: 33.5% vs. 
46.9%, p=0.004; severe PPM: 6.7% vs. 15.6%, p=0.003). The lower frequency of severe 
PPM in SEV was observed even in patients with larger annulus. While patients with BSA 
>1.83 m2 had a significantly lower incidence of PPM with SEV compared to BEV, there 
was no significant difference in patients with BSA ≤1.83 m2. We found no impact of PPM 
on cardiovascular mortality or NYHA functional class at 1 year.  
Conclusions: SEV were associated with a lower frequency of PPM compared to BEV 
irrespective of annulus area. The difference was mainly driven by larger patients with 
BSA >1.83 m2.  
CONDENSED ABSTRACT 
We performed a propensity score matched comparison of prosthesis-patient mismatch 
(PPM) between self-expandable valves (SEV) and balloon-expandable valves (BEV). 
SEV were significantly associated with a lower incidence of PPM compared with BEV 
(PPM: 33.5% vs. 46.9%, p=0.004; severe PPM: 6.7% vs. 15.6%, p=0.003; respectively). 
The difference was independent of annulus sizes or valve sizes, but was driven by larger 
patients with BSA > 1.83m2 (PPM: 45.3% vs. 60.9%, p=0.021; severe PPM: 8.5% vs. 
22.6%, p=0.004), while there was no significant difference in smaller patients with BSA 
≤1.83 m2 (PPM: 22.9% vs. 32.1%, p=0.120; severe PPM: 5.1% vs. 8.3%, p=0.341). 
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ABBREVIATION AND ACRONYMS 
 
AVC = Aortic valvular complex 
BSA = Body surface area 
CT = Computed tomography 
EOA = Effective orifice area 
LVOT = Left ventricular outflow tract 
PPM = Prosthesis-patient mismatch 
SAVR = Surgical aortic valve replacement 
STS PROM= Society of Thoracic Surgery-Predicted Risk Of Mortality 
TAVR = Transcatheter aortic valve replacement 
VARC = Valve Academic Research Consortium 
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Introduction 
Prosthesis-patient mismatch (PPM) has been a topic of debate ever since it was 
first conceived by Rahimtoola in 1978(1). Recently, transcatheter aortic valve 
replacement (TAVR) has evolved as an alternative to surgical aortic valve replacement 
(SAVR) in various clinical settings and has been associated with superior hemodynamic 
performance and a lower incidence of PPM(2,3). A retrospective analysis of  62,125 
patients enrolled in the STS (Society of Thoracic Surgeons)/ACC (American College of 
Cardiology) TVT (Transcatheter Valve Therapy) registry reported that the rate of severe 
PPM following TAVR was approximately 12% and was associated with higher mortality 
and heart failure rehospitalization at 1 year follow-up(4). 
PPM occurs when the effective orifice area (EOA) of the prosthesis is too small 
relative to the patient’s body size. Self-expandable transcatheter heart valves (SEV) are 
supra-annular in position allowing for a larger EOA and thereby potentially preventing 
PPM as compared to balloon-expandable valves (BEV) which have an intra-annular 
position(5). The aim of the present analysis is therefore to compare the frequency of PPM 
with SEV to BEV.  
Accepted author’s manuscript.  JACC. Cardiovascular interventions. 
Publisher DOI: https://doi.org/10.1016/j.jcin.2019.07.027  
 
 6 
 
Methods 
Study population 
All patients undergoing TAVR at Bern University Hospital, Bern, Switzerland, are 
consecutively enrolled into a prospective institutional registry that is a part of the Swiss 
TAVI registry (NCT01368250). The registry has been approved by the local ethics 
committee, and patients provide written informed consent to participate. For the purpose 
of the present analysis, we analyzed all patients treated with SEV (CoreValve and Evolut 
R, Medtronic, Minneapolis, MN, USA) and those treated with BEV (SAPIEN THV/XT 
and SAPIEN 3, Edwards Lifesciences, Irvine, CA, USA). Patients without hemodynamic 
assessment by post-procedural echocardiography or pre-procedural CT raw data adequate 
for a comprehensive assessment of aortic valvular complex (AVC) were excluded from 
the analysis. 
Transcatheter aortic valve replacement 
In the majority of cases, TAVR was performed by transfemoral access. In patients 
who could not undergo transfemoral access due to calcified, tortuous or small caliber 
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vessels, transapical or transsubclavian access was used. Prosthesis selection was based on 
CT anatomical assessment and clinical suitability of each patient. Post-procedural care 
included rhythm monitoring for at least 48h after the intervention, laboratory testing, and 
daily 12-lead electrocardiograms directly after the procedure and then on a daily basis.  
Echocardiographic assessment 
Standardized transthoracic echocardiography was performed before and after 
TAVR by a board-certified cardiologist and assessed in accordance to the Valve Academic 
Research Consortium (VARC-2) recommendations(6). EOA was assessed using the 
continuity equation and indexed to the body surface area (BSA). The mean transaortic 
valve gradient was measured using continuous-wave Doppler. Post-procedural 
regurgitation severity was evaluated using a multiparametric approach and classified as 
follows: none/trace, mild, moderate, and severe. PPM was classified based on discharge 
prosthetic EOA indexed to BSA as severe (<0.65 cm2/m2) or moderate (0.65 to 0.85 
cm2/m2) in the general population, and as severe (<0.60 cm2/m2) or moderate (0.60 to 
0.90 cm2/m2) in the obese population (BMI ≥ 30 kg/m2).  
Data collection and clinical follow-up 
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Baseline clinical data, procedural characteristics, and follow-up data were entered 
into a dedicated database, which is verified and maintained by the Clinical Trials Unit of 
the University of Bern. Clinical follow-up was scheduled at 30 days and 1 year using 
standardized interviews, documentation from referring physicians, and hospital discharge 
summaries. All target events were systematically collected and adjudicated by a dedicated 
clinical event committee, involving cardiologists and cardiac surgeons, according to the 
VARC-2 criteria(6).  
Statistical analysis 
Categorical data are represented as frequencies and percentages and the 
differences between groups are evaluated with the Chi-square test or Fisher’s exact test. 
Continuous variables are expressed as mean values ± standard deviation and compared 
between groups using t tests. 
Because the valve type and size selection was based on CT anatomical assessment 
and clinical suitability of each patient, which could significantly affect the hemodynamic 
result of the implanted valve, we applied a propensity score matching method to control 
for these confounding baseline variables. Propensity score was modelled using a 
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multivariate logistic regression model based on the following baseline variables: age, sex, 
BSA(cm2), STS PROM(%), atrial fibrillation, peripheral artery disease, left ventricular 
ejection fraction(%), moderate or severe mitral regurgitation (MR), moderate or severe 
tricuspid regurgitation (TR), as well as CT measured variables: bicuspid valve, annulus 
area (mm2), AVC calcium volume (mm3), left ventricular out flow tract (LVOT) calcium 
volume (mm3), aortic angulation, and annulus eccentricity (=minimum annulus 
diameter/maximum annulus diameter). These variables were selected based on their 
presumed association with prosthesis selection and hemodynamic outcome. We matched 
patients treated with SEV and BEV using propensity score with a caliper of 0.2. All main 
analyses presented are on this propensity score matched cohort. 
 Univariate logistic regression was used to estimate the effect of the valve type on 
the incidence of PPM. Event-free survival curves were constructed using the Kaplan-
Meier method and Cox proportional hazards models were used to calculate crude hazard 
ratios (HR) and 95% confidence intervals (95% CI). Pearson’s correlation coefficients 
and Spearman’s rank correlation coefficients were used to measure associations between 
variables. Fisher’s tests, chi-square test or multinomial models were used to test 
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relationships between variables and PPM. A multinomial model was applied when the 
response variables were categorical (valve sizes and PPM incidence). Odds ratios (OR 
with 95% confidence interval) are given for effect sizes, where appropriate. Throughout 
the present study, a p-value of <0.05 was considered significant. Statistical analyses were 
performed using Stata 15.1 (StataCorp, College Station, TX, USA). 
 
Results 
Propensity score matching and patient populations 
Among 1811 consecutive patients undergoing TAVR between August 2007 and 
June 2017, a total of 757 patients met the inclusion criteria and were eligible for the 
present analysis. Among them, 420 patients were treated with BEV (SAPIEN THV/XT 
and SAPIEN 3) and 337 patients were treated with SEV (CoreValve and Evolut R). 
Propensity score matching resulted in 224 matched pairs. The baseline characteristics of 
the unmatched and matched population are shown in Table 1. Before propensity score 
matching, there were significant differences in annulus area/perimeter, LVOT calcium 
volume, and aortic angulation between the two groups. After propensity score matching, 
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baseline characteristics including the CT assessment data were well balanced between the 
two groups.  
Procedural characteristics and clinical outcomes 
Procedural characteristics and clinical outcomes are summarized in Table 2. Pre-
dilatation rate was significantly lower, whereas post-dilatation rate was significantly 
higher in the SEV group. Valve dislocation or embolization was observed in 5.5% in the 
SEV group, which was significantly higher compared with 0.5% in the BEV group 
(p=0.004). Clinical follow-up at 30 days was complete in all patients and the outcomes 
were comparable between the two groups, except for a higher rate of new permanent 
pacemaker implantation in the SEV group (31.7% vs. 13.8%, OR [95% CI]: 2.9 [1.8-4.6], 
p<0.001). 
Echocardiographic outcomes and PPM 
Echocardiographic outcomes at discharge are shown in Table 3. The incidence of 
moderate or severe post-procedural aortic regurgitation (AR) was significantly higher in 
the SEV group (13% vs. 6%, OR [95% CI]: 2.2 [1.1-4.3], p =0.021). EOA and EOA 
indexed to the BSA (iEOA) were significantly higher in the SEV group as compared to 
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the BEV group (1.80 ± 0.46 vs. 1.68 ± 0.52, p = 0.010; 0.99 ± 0.27 vs. 0.93 ± 0.31, p = 
0.021; respectively), and mean transvalvular gradients were 8.28 ± 3.87 mmHg in the 
SEV group and 10.68 ± 4.65 mmHg in the BEV group (p<0.001). Consequently, SEV 
were significantly associated with a lower rate of PPM compared with BEV (PPM: 33.5% 
vs. 46.9%, OR [95% CI]: 0.57 [0.39-0.84], p=0.004; severe PPM: 6.7% vs. 15.6%, OR 
[95% CI]: 0.39 [0.21-0.73], p=0.003) as shown in Central illustration. Subgroup 
analyses were performed to investigate the effect of annulus size and BSA on the 
incidence of PPM (Central illustration). Subgroups based on annulus area and BSA 
were divided into 2 groups using the specified cut-off values. The annulus area was 
divided at 430 mm2, which is a cut-off value between 23mm and 26mm of SAPIEN 3, 
and the BSA was divided at the mean value of the analyzed population. Among patients 
with small annuli (< 430 mm2), PPM was more common (51.1% vs. 29.9%, p=0.003) and 
severe PPM occurred numerically more frequently (13.6% vs. 8.6%, p=0.284) in the BEV 
group. Among patients with larger annulus (≥ 430 mm2), PPM was numerically more 
common (44.1% vs. 36.6%, p=0.214) and severe PPM occurred significantly more often 
(16.9% vs. 5.3%, p=0.004) in the BEV group. Both PPM and severe PPM occurred 
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significantly more often in the BEV group as compared to the SEV group in the subset of 
larger BSA (60.9% vs. 45.3%, p=0.021; 22.6% vs. 8.5%, p=0.004; respectively), whereas 
the rates of PPM and severe PPM were comparable in the subset of patients with smaller 
BSA (32.1% vs. 22.9%, p=0.120; 8.3% vs. 5.1%, p=0.341; respectively). There were no 
interaction effects both in annulus area divided at 430 mm2 (p=0.117 for PPM, p=0.685 
for severe PPM) and BSA divided at 1.83 m2 (p=0.247 for PPM, p=0.358 for severe PPM). 
EOAi and PPM rate according to the valve type and size are summarized in Table 4. As 
shown, there was no increase in EOAi according to increased valve size. The effect of the 
valve size on the incidence rates of moderate or severe PPM was examined by a 
multinomial model and there was no significant effect (p=0.37). 
Impact of PPM on clinical outcomes 
Clinical outcome data was available in 446 patients (99.6%), 1 patient refused 
follow-up and 1 patient was not traceable. Kaplan-Meier curves of cardiovascular 
mortality according to PPM are shown in Figure 1. Cumulative mortality rate at 1 year 
in patients with severe PPM was numerically higher as compared to patients with 
moderate PPM and without PPM (10.3% vs. 6.3% vs. 6.6%; Severe PPM vs. No PPM 
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HR [95% CI]: 1.60 [0.59-4.34], p=0.355; Moderate PPM vs. No PPM HR [95% CI]: 0.96 
[0.42-2.23], p=0.929; Severe PPM vs. No or Moderate PPM HR [95% CI]: 1.62 [0.62-
4.24], p=0.324). New York Heart Association functional class at 1 year did not differ 
significantly between patients with no PPM, moderate PPM, and severe PPM (p=0.84, 
Figure 2). 
 
Discussion 
The key findings of this propensity score matched analysis comparing SEV 
(supra-annular valves) and BEV (intra-annular valves) are as follows: 1) The rate of PPM 
was significantly lower in SEV as compared to BEV (PPM: 33.5% vs. 46.9%, p=0.004; 
severe PPM: 6.7% vs. 15.6%, p=0.003); 2) The effect was consistent across different 
annulus sizes and driven by larger patients with BSA >1.83 m2. Previous analyses have 
used an alternative definition of PPM without adjustment for BMI (2-4, 7-9, 13, 14). We 
found consistent findings irrespective of which definition was used and provide an 
analysis using an alternative definition of PPM in the Online Supplement (Online Figure 
1). 
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The concept of PPM has originally been described in 1978(1), since then 
numerous studies have investigated the incidence of PPM and the potential effects  on 
clinical outcomes. Although previous studies have shown a lower incidence of PPM in 
TAVR compared to SAVR(2,3,7,8), moderate PPM and severe PPM still occurred in 9 to 
36% and 1 to 28% of the patients, respectively(2-4,7-13). BEV are constrained by the 
native valve area, whereas SEV can achieve a larger EOA by being situated above the 
native valve allowing more space and have been suggested to be associated with less PPM. 
However, there is limited data demonstrating a relationship between SEV and PPM. 
Nombela-Franco et al. reported similar rates of severe PPM between CoreValve and 
SAPIEN prostheses within patients receiving the same prosthesis size (26mm) in a 
propensity score matched analysis(14). More recently, Mauri et al. demonstrated a lower 
incidence of PPM in patients treated with ACURATE neo (Boston Scientific, 
Marlborough, Massachusetts, USA), which is also a self-expandable and supra-annular 
position valve, as compared to SAPIEN 3 in patients with small annulus area 
(<400mm2)(11). In clinical practice, valve selection is based on CT assessment such as 
annulus size, AVC calcium, and annulus eccentricity, which may directly influence the 
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prosthesis EOA after implantation. These potential confounding factors need to be taken 
into account. We applied propensity score matching analysis adjusting for these 
confounding factors to compare SEV and BEV, and found a significantly lower incidence 
of PPM and severe PPM in SEV compared to BEV. 
  To date, patients with small aortic annuli have been considered to have a greater 
risk of PPM and therefore previous studies focused on this population when investigating 
PPM(11,15). However, in our data, BEV was associated with higher rate of PPM as 
compared to SEV even in patients with relatively larger annulus area (≥430 mm2). 
Moreover, the larger valve size did not result in a lower incidence of moderate or severe 
PPM. This was likely due to patients treated with larger valve sizes tending to have larger 
body sizes (r=0.277, p<0.001). Annulus area, which fundamentally determines valve size, 
had a weak but positive correlation with BSA (r=0.356, p<0.001) (Online Figure 2). On 
the other hand, the incidence of PPM was comparable between BEV and SEV in patients 
with smaller BSA (≤1.83m2). Therefore, BSA seems to be the more important factor 
indicating vulnerability to PPM rather than annulus size. It might be necessary to select 
the valve type considering the risk of PPM in patients with relatively large body sizes 
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even if the annulus size is not too small, while keeping in mind higher possible risk of 
valve dislocation or embolization, permanent pacemaker implantation, and post-
procedural AR. 
There is conflicting evidence on the impact of PPM on clinical outcome, likely 
due to methodological differences across the studies and the patient population being 
studied(16-18). In the present study, neither moderate PPM nor severe PPM significantly 
predicted cardiovascular mortality or NYHA functional class at 1 year. In contrast to a 
previous study(2), severe PPM did not predict mortality in our cohort in a sensitivity 
analysis excluding patients with significant post-procedural AR (Online Figure 3a). 
Moreover, we found no effect of PPM on mortality after exclusion of patients with 
moderate or severe MR (Online Figure 3b). This is in line with the results from some of 
the previous studies in TAVR(7,9,11,12), whereas some other studies demonstrated 
adverse effects of PPM on mortality or NYHA functional class(2,4,8,10). PPM increases 
left ventricular (LV) afterload, which may impair coronary flow reserve(19). It also 
impedes regression of LV hypertrophy and dysfunction(2,8,10,20), and attenuates 
improvement of MR(21). PPM has also been suggested to be associated with other 
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adverse outcomes such as abnormalities of the Von Willebrand factor caused bleeding 
complications(22), exercise-induced arrhythmias(23), and congestive heart failure(4,24). 
Although there were inconsistent results regarding the association of PPM with mortality 
in SAVR(16) as in TAVR, a large meta-analysis of 34 observational studies comprising 
27,186 patients demonstrated an increased mortality in patients with PPM(17). Our study 
included a modest number of patients with limited duration of follow-up and may 
therefore be underpowered to demonstrate a clinical impact of PPM. Moreover, some 
studies in SAVR have suggested that the impact of PPM on mortality was only observed 
in younger patients (age < 60 or 70 years old) with a more active life style(25,26). This 
may explain at least in part why we failed to demonstrate a clinical impact of PPM in our 
cohort, in which the average age was over 80 years of age. PPM is also suggested to be 
an important risk factor for early structural valve deterioration and re-intervention(18,27). 
Therefore, further studies with a younger population and with longer follow-up are 
needed to investigate the clinical importance of PPM as a modifiable risk factor for 
mortality, heart failure, and valve deterioration. 
Study Limitations 
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  Our results should be interpreted in light of several limitations. We did not use an 
independent core laboratory. However, our measurements are consistent with previously 
reported core lab analyses for EOA(28). The EOA measurement by Doppler 
echocardiography may be affected by technical pitfalls or measurement errors and the 
accuracy and reproducibility could not be assessed. Although we applied propensity score 
matched analysis in order to adjust for important confounders including annulus size, 
which could significantly affect the hemodynamic results of the procedure, unknown 
confounders might be present. Finally, longer follow-up and inclusion of younger patients 
might be necessary to evaluate the impact of PPM on clinical outcomes more 
comprehensively. 
 
Conclusion 
  SEV had a preventative effect on PPM as compared to BEV in general and even 
in patients with relatively larger annulus size. The difference was mainly driven by 
patients with larger body size. Although PPM did not affect clinical outcomes in the 
present analysis, further investigation is required to evaluate the clinical significance of 
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PPM. 
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PERSPECTIVES 
WHAT IS KNOWN: The supra-annular position of self-expandable valves (SEV) may 
increase effective orifice area and prevent prosthesis-patient mismatch (PPM), a risk 
factor for adverse clinical outcomes. Moreover, patients with small aortic annuli are 
considered high risk for PPM and may particularly benefit from SEV. However, there 
were few direct comparison of SEV and balloon-expandable valves (BEV) with regard 
to the incidence of PPM in real clinical practice. 
 
WHAT IS NEW: SEV are associated with a significantly lower incidence of PPM as 
compared to BEV in general and even in patients with relatively larger annuli. The 
difference was largely driven by patients with larger body sizes (BSA > 1.83 m2).  
 
WHAT IS NEXT: Future risk prediction models to identify patients at higher risk of PPM 
and may benefit from SEV are expected. Further studies with a younger population and 
with longer follow-up are needed to investigate the clinical importance of PPM as a 
modifiable risk factor for mortality, heart failure, and valve deterioration.  
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 Figure Legends 
Central illustration. Prosthesis-patient mismatch (PPM) according to the valve 
type. 
A. The rate of PPM was significantly lower in self-expandable valves (SEV) 
compared to balloon-expandable valves (BEV). 
B. SEV were associated with a significantly lower rate of PPM and numerically 
lower rate of severe PPM in the subset of smaller annulus area (<430mm2). In the 
subset of larger annulus area (≥430mm2), SEV were associated with numerically 
lower incidence of PPM and significantly lower incidence of severe PPM. SEV were 
associated with significantly lower incidences of PPM and severe PPM in the subset 
of larger BSA (>1.83m2), whereas the incidences were comparable between SEV and 
BEV in the subset of smaller BSA (≤1.83m2). The p value for the interaction between 
SEV use and annulus area for PPM and severe PPM was not significant (p=0.117, 
p=0.685, respectively). The p value for the interaction between SEV use and BSA for 
PPM and severe PPM was not significant either (p=0.247, p=0.358, respectively). 
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Figure 1. Kaplan-Meier curves of cardiovascular death according to the presence 
of PPM.  
Cumulative mortality rate at 1 year in patients with severe PPM was numerically 
higher as compared to patients with moderate PPM and without PPM (10.3% vs. 
6.3% vs. 6.6%; Severe PPM vs. No PPM HR [95% CI]: 1.60 [0.59-4.34], p=0.355; 
Moderate PPM vs. No PPM HR [95% CI]: 0.96 [0.42-2.23], p=0.929; Severe PPM 
vs. No or Moderate PPM HR [95% CI]: 1.62 [0.62-4.24], p=0.324). Blue line 
indicates no PPM; orange line indicates moderate PPM; red line indicates severe 
PPM.  
 
Figure 2. New York Heart Association (NYHA) functional class at one year 
according to the presence of moderate or severe PPM.  
NYHA functional class at one year did not differ significantly among no PPM, 
moderate PPM, and severe PPM (p=0.84). 
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Tables 
Table 1. Baseline characteristics of the unmatched and matched population 
 
Unmatched Cohort Matched Cohort 
Intra-annular 
valves 
(SAPIEN 
THV/XT/3) 
(n=420) 
Supra-annular 
valves 
(CoreValve, 
Evolut R) 
(n=337) 
p-value 
Intra-annular 
valves 
(SAPIEN 
THV/XT/3) 
(n=224) 
Supra-annular 
valves 
(CoreValve, 
Evolut R) 
(n=224) 
p-value 
 
Age (years) 82.3 ± 5.8 82.7 ± 5.6 0.417 82.9 ± 5.6 82.9 ± 5.4 0.999 
Female gender (n, %) 201 (47.9%) 199 (59.1%) 0.003 116 (51.8%) 114 (50.9%) 0.925 
Body mass index (kg/m2) 27.0 ± 5.0 26.4 ± 5.5 0.125 26.8 ± 5.2 26.9 ± 5.8 0.885 
Body surface area (m2) 1.87 ± 0.23 1.81 ± 0.24 0.001 1.84 ± 0.24 1.84 ± 0.25 0.861 
STS PROM (%) 5.02 ± 3.23 5.90 ± 3.91 0.001 5.65 ± 3.69 5.28 ± 3.22 0.258 
NYHA functional class Ⅲ/Ⅳ
(n, %) 
289 (68.8%) 247 (73.3%) 0.198 157 (70.1%) 160 (71.4%) 0.835 
Concomitant diseases 
Arterial hypertension (n, %) 358 (85.2%) 292 (86.6%) 0.601 198 (88.4%) 195 (87.1%) 0.774 
Diabetes mellitus (n, %) 107 (25.5%) 84 (24.9%) 0.867 61 (27.2%) 58 (25.9%) 0.831 
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Dyslipidemia (n, %) 270 (64.3%) 210 (62.3%) 0.596 149 (66.5%) 143 (63.8%) 0.620 
CKD (eGFR<60) (n, %) 261 (62.1%) 228 (67.7%) 0.126 148 (66.1%) 144 (64.3%) 0.766 
COPD (n, %) 49 (11.7%) 49 (14.5%) 0.276 29 (12.9%) 31 (13.8%) 0.890 
Atrio-ventricular block (n, %) 77 (20.9%) 63 (24.6%) 0.285 44 (22.7%) 39 (23.5%) 0.900 
Atrial fibrillation (n, %) 131 (31.2%) 109 (32.3%) 0.754 72 (32.1%) 72 (32.1%) 1.000 
Previous history 
Coronary artery disease (n, %) 267 (63.6%) 202 (59.9%) 0.328 143 (63.8%) 146 (65.2%) 0.843 
History of cerebrovascular 
accident (n, %) 49 (11.7%) 36 (10.7%) 0.729 29 (12.9%) 20 (8.9%) 0.226 
Peripheral artery disease 
(n, %) 30 (7.1%) 48 (14.2%) 0.002 22 (9.8%) 24 (10.7%) 0.876 
Laboratory data 
Hemoglobin (g/dl) 122.5 ± 16.6 122.3 ± 16.9 0.851 122.2 ± 16.5 123.8 ± 16.9 0.295 
BNP level (pg/ml) 510.1 ± 702.0 630.8 ± 863.2 0.054 584.9 ± 800.5 585.4 ± 809.8 0.996 
Echocardiographic data 
Aortic valve area (cm2) 0.68 ± 0.23 0.63 ± 0.26 0.008 0.66 ± 0.23 0.65 ± 0.26 0.740 
Aortic valve mean gradient 
(mmHg) 42.0 ± 16.0 42.6 ± 18.5 0.667 40.8 ± 16.0 41.9 ± 17.1 0.493 
LVEF (%) 55.8 ± 14.0 54.7 ± 14.6 0.259 54.5 ± 14.9 54.9 ± 13.7 0.750 
Moderate/severe AR (n, %) 27 (7.1%) 32 (10.7%) 0.102 16 (7.8%) 15 (7.6%) 1.000 
Moderate/severe MR (n, %) 51 (13.2%) 65 (21.0%) 0.008 31 (14.9%) 42 (20.5%) 0.156 
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Moderate/severe TR (n, %) 30 (8.4%) 35 (14.1%) 0.032 17 (8.8%) 18 (11.1%) 0.479 
Computed tomography data 
Bicuspid valve (n, %) 33 (7.9%) 22 (6.5%) 0.573 15 (6.7%) 12 (5.4%) 0.692 
Annulus area (mm²) 470.2 ± 84.0 446.7 ± 99.5 <0.001 459.5 ± 86.8 459.8 ± 85.7 0.963 
Annulus perimeter (mm) 78.1 ± 6.9 76.1 ± 8.2 <0.001 77.3 ± 7.3 77.3 ± 7.1 0.968 
AVC calcium (mm³) 348.4 ± 322.1 319.3 ± 332.6 0.223 338.1 ± 317.7 334.8 ± 356.8 0.918 
LVOT calcium (mm³) 12.5 ± 32.3 20.3 ± 59.8 0.023 15.6 ± 34.5 17.0 ± 41.1 0.710 
Porcelain Aorta (n, %) 17 (4.0%) 17 (5.1%) 0.597 7 (3.1%) 9 (4.0%) 0.800 
Aortic Angulation (°) 50.5 ± 9.5 47.9 ± 10.1 <0.001 49.3 ± 9.1 49.1 ± 10.0 0.824 
Eccentricity of annulus (0-1) 0.77 ± 0.06 0.76 ± 0.06 0.081 0.77 ± 0.06 0.76 ± 0.06 0.903 
AR = Aortic regurgitation; AVC = Aortic valvular complex; BNP = Brain natriuretic peptide; COPD = Chronic obstructive pulmonary 
disease; CKD = Chronic kidney disease; LV = Left ventricle; LVEF = Left ventricular ejection fraction; LVOT = left ventricular outflow 
tract; MR = Mitral regurgitation; NYHA = New York Heart Association; STS = Society of Thoracic Surgeons; TR = Tricuspid 
regurgitation. 
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Table 2. Procedural characteristics, complications, and clinical outcomes of the matched population 
  
  
  Intra-annular valves (SAPIEN THV/XT/3) 
(n=224) 
Supra-annular valves 
(CoreValve, Evolut R) 
(n=224) 
p-value 
Procedural characteristics 
 
Pre-dilatation (n, %) 179 (79.9%) 153 (68.3%) 0.007 
Post-dilatation (n, %) 40 (17.9%) 87 (38.8%) <0.001 
Procedural Complications 
 Major Vascular complication 27 (12.1%) 24 (10.7%) 0.766 
 Valve in series (n, %) 1 (0.4%) 6 (2.7%) 0.122 
 Annulus rupture/aortic dissection (n, %) 0 (0.0%) 0 (0.0%)  
 Valve dislocation/embolization (n, %) 1 (0.5%) 10 (5.5%) 0.004 
 Coronary artery occlusion (n, %) 3 (1.4%) 0 (0.0%) 0.252 
Post-procedural Clinical outcomes (at 30 days) 
 Mortality 6 (2.7%) 2 (0.9%) 0.285 
 Myocardial Infarction 3 (1.3%) 3 (1.3%) 1.000 
 Disabling stroke 3 (1.3%) 1 (0.4%) 0.623 
 Bleeding: Life-threatening 11 (4.9%) 12 (5.4%) 1.000 
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 Bleeding: Major 23 (10.3%) 32 (14.3%) 0.249 
 Kidney injury Stage3 5 (2.2%) 8 (3.6%) 0.575 
 Permanent Pacemaker Implantation 31 (13.8%) 71 (31.7%) <0.001 
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Table 3. Echocardiographic outcomes at discharge according to type of valve in the matched population 
  Intra-annular valves 
(SAPIEN THV/XT/3) 
(n=224) 
Supra-annular valves 
(CoreValve, Evolut R) 
(n=224) 
p value 
Discharge 
EOA (cm2) 1.68 ± 0.52 1.80 ± 0.46 0.010 
indexed EOA (cm2/m2) 0.93 ± 0.31 0.99 ± 0.27 0.021 
Transvalvular mean gradient (mmHg) 10.7 ± 4.7 8.3 ± 3.9 <0.001 
LVEF (%) 56.5 ± 11.5 56.5 ± 10.8 0.959 
PPM (n, %) 105 (46.9%) 75 (33.5%) 0.004 
 Moderate PPM (n, %) 70 (31.3%) 60 (26.8%) 0.298 
 Severe PPM (n, %) 35 (15.6%) 15 (6.7%) 0.003 
≥ moderate AR (n, %) 14 (6.4%) 29 (13.0%) 0.021 
≥ moderate MR (n, %) 25 (11.6%) 23 (12.5%) 0.775 
≥ moderate TR (n, %) 20 (9.4%) 23 (12.8%) 0.289 
AR = Aortic regurgitation; EOA = Effective orifice area index; LVEF = Left ventricular ejection fraction; MR 
= Mitral regurgitation; PPM = prosthesis-patient mismatch; TR = tricuspid regurgitation. 
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Table 4. Post-procedural EOAi and PPM rate according to valve type and sizes in the matched population 
Intra-annular valves 
(SAPIEN THV/XT/3) 
(n=224) 
Supra-annular valves 
(CoreValve, Evolut R) 
(n=224) 
Valve size 
(n) 
EOAi 
(cm²/m²) 
Moderate 
PPM (%) 
Severe PPM 
(%) 
Valve size 
(n) 
EOAi 
(cm²/m²) 
Moderate 
PPM (%) 
Severe PPM 
(%) 
23-mm 
(n=68) 0.88 ± 0.29 25 (36.8%) 12 (17.6%) 
23-mm 
(n=1) 0.86  0 (0.0%) 0 (0.0%) 
26-mm 
(n=106) 0.98 ± 0.32 32 (30.2%) 11 (10.4%) 
26-mm 
(n=67) 1.03 ± 0.30  14 (20.9%) 6 (9.0%) 
29-mm 
(n=50) 0.88 ± 0.30  13 (26.0%) 12 (24.0%) 
29-mm 
(n=109) 1.00 ± 0.26  31 (28.4%) 4 (3.7%) 
 
  
31-mm 
(n=40) 0.91 ± 0.24  13 (32.5%) 4 (10.0%) 
34-mm 
(n=7) 0.93 ± 0.33  2 (28.6%) 1 (14.3%) 
BSA = body surface area; EOAi = Effective orifice area index; PPM = Prosthesis-patient mismatch. 
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Central Figure 
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Figure 1. 
 
Figure 2. 
 
 
 
